Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management

Published:2023-05-15 Issue:5 Volume:14 Page:549-559
ISSN:1948-9358
Container-title:World Journal of Diabetes
language:
Short-container-title:World J Diabetes

Author:

Wibawa I Dewa Nyoman,Mariadi I Ketut,Somayana Gde,Krisnawardani Kumbara Cokorda Istri Yuliandari,Sindhughosa Dwijo Anargha

Publisher

Baishideng Publishing Group Inc.

Subject

Industrial and Manufacturing Engineering,Surfaces, Coatings and Films

Reference74 articles.

1. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?

2. Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

4. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

5. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3